ATE388139T1 - Pyridone als hemmer der sh2-domäne der src- familie - Google Patents
Pyridone als hemmer der sh2-domäne der src- familieInfo
- Publication number
- ATE388139T1 ATE388139T1 AT98962022T AT98962022T ATE388139T1 AT E388139 T1 ATE388139 T1 AT E388139T1 AT 98962022 T AT98962022 T AT 98962022T AT 98962022 T AT98962022 T AT 98962022T AT E388139 T1 ATE388139 T1 AT E388139T1
- Authority
- AT
- Austria
- Prior art keywords
- pyridone
- inhibitor
- domain
- src family
- src
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6997197P | 1997-12-18 | 1997-12-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE388139T1 true ATE388139T1 (de) | 2008-03-15 |
Family
ID=22092332
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT98962022T ATE388139T1 (de) | 1997-12-18 | 1998-12-09 | Pyridone als hemmer der sh2-domäne der src- familie |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US6054470A (de) |
| EP (1) | EP1045836B1 (de) |
| JP (1) | JP4524039B2 (de) |
| AR (1) | AR017895A1 (de) |
| AT (1) | ATE388139T1 (de) |
| AU (1) | AU1719499A (de) |
| CA (1) | CA2315113C (de) |
| CO (1) | CO4990963A1 (de) |
| DE (1) | DE69839221T2 (de) |
| ES (1) | ES2302363T3 (de) |
| UY (1) | UY25313A1 (de) |
| WO (1) | WO1999031066A1 (de) |
| ZA (1) | ZA9811570B (de) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002542190A (ja) * | 1999-04-15 | 2002-12-10 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | リン酸化チロシン模倣物として有用な化合物 |
| US6777433B2 (en) | 1999-12-22 | 2004-08-17 | Merck Frosst Canada & Co. | Protein tyrosine phosphatase 1B (PTP-1B) inhibitors containing two ortho-substituted aromatic phosphonates |
| CA2393363A1 (en) | 1999-12-22 | 2001-06-28 | Merck Frosst Canada & Co. | Phosphonic acid derivatives as inhibitors of protein tyrosine phosphatase 1b (ptp-1b) |
| JP2003518130A (ja) | 1999-12-22 | 2003-06-03 | メルク フロスト カナダ アンド カンパニー | 蛋白チロシンホスファターゼ１ｂ（ｐｔｐ−１ｂ）阻害薬としてのホスホン酸誘導体 |
| US6486141B2 (en) | 1999-12-22 | 2002-11-26 | Merck Frosst Canada & Co. | Phosphonic acid biaryl derivatives as inhibitors of protein tyrosine phosphatase 1B (PTP-1B) |
| AU2001243601A1 (en) * | 2000-03-10 | 2001-09-24 | Ariad Pharmaceuticals, Inc. | Caprolactam derivatives and uses thereof |
| US6465444B2 (en) | 2000-03-22 | 2002-10-15 | Merck Frosst Canada & Co. | Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors |
| PE20011350A1 (es) | 2000-05-19 | 2002-01-15 | Vertex Pharma | PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE) |
| ATE438624T1 (de) | 2000-12-28 | 2009-08-15 | Shionogi & Co | 2-pyridonderivate mit affinität für den cannabinoid-typ-2-rezeptor |
| IL141647A0 (en) | 2001-02-26 | 2002-03-10 | Yeda Res & Dev | Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus |
| EP1465869B1 (de) * | 2001-12-21 | 2013-05-15 | Exelixis Patent Company LLC | Modulatoren von lxr |
| US7482366B2 (en) | 2001-12-21 | 2009-01-27 | X-Ceptor Therapeutics, Inc. | Modulators of LXR |
| MXPA05007552A (es) | 2003-01-14 | 2006-05-19 | Teva Pharma | Formulaciones parenterales de un peptido para el tratamiento de lupus sistemico eritematoso. |
| US20050119163A1 (en) * | 2003-09-18 | 2005-06-02 | The Government Of The United States Of America, As Represented By The Secretary, | SH2 domain binding inhibitors |
| PT2399916E (pt) | 2004-03-12 | 2015-03-17 | Vertex Pharma | Processo e intermediários para a preparação de inibidores de caspase de acetal de ácido aspártico |
| EP1768662A2 (de) | 2004-06-24 | 2007-04-04 | Novartis Vaccines and Diagnostics, Inc. | Immunstimulatoren kleiner moleküle und assays für deren nachweis |
| TWI417095B (zh) | 2006-03-15 | 2013-12-01 | Janssen Pharmaceuticals Inc | １，４-二取代之３-氰基-吡啶酮衍生物及其作為ｍＧｌｕＲ２-受體之正向異位性調節劑之用途 |
| TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
| TW200845978A (en) | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
| TWI448284B (zh) * | 2007-04-24 | 2014-08-11 | Theravance Inc | 雙效抗高血壓劑 |
| PL2203439T3 (pl) | 2007-09-14 | 2011-06-30 | Addex Pharmaceuticals Sa | 1',3'-dipodstawione-4-fenylo-3,4,5,6-tetrahydro-2H, 1'H-[1, 4']bipirydynylo-2'-ketony |
| ES2439291T3 (es) | 2008-09-02 | 2014-01-22 | Janssen Pharmaceuticals, Inc. | Derivados de 3-azabiciclo[3.1.0]hexilo como moduladores de receptores de glutamato metabotrópicos |
| ES2401691T3 (es) | 2008-11-28 | 2013-04-23 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc. | Derivados de indol y de benzoxacina como moduladores de los receptores metabotrópicos de glutamato |
| WO2010091164A1 (en) * | 2009-02-06 | 2010-08-12 | Exelixis, Inc. | Inhibitors of glucosylceramide synthase |
| AU2010246607B2 (en) | 2009-05-12 | 2012-09-27 | Addex Pharma S.A. | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors |
| MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| JP5634506B2 (ja) | 2009-05-12 | 2014-12-03 | ジャンセン ファーマシューティカルズ， インコーポレイテッド | １，２，３−トリアゾロ［４，３−ａ］ピリジン誘導体ならびに神経障害および精神障害の治療または予防のためのその使用 |
| JP5852665B2 (ja) | 2010-11-08 | 2016-02-03 | ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド | １，２，４−トリアゾロ［４，３−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体のポジティブアロステリックモジュレーターとしてのそれらの使用 |
| ES2552455T3 (es) | 2010-11-08 | 2015-11-30 | Janssen Pharmaceuticals, Inc. | Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2 |
| JP5852666B2 (ja) | 2010-11-08 | 2016-02-03 | ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド | １，２，４−トリアゾロ［４，３−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体のポジティブアロステリックモジュレーターとしてのそれらの使用 |
| CA2914178C (en) | 2013-01-07 | 2023-06-13 | University Of Southern California | Deoxyuridine triphosphatase inhibitors |
| JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
| JO3367B1 (ar) | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2 |
| CN106061952B (zh) | 2014-01-03 | 2022-01-28 | 南加州大学 | 含有杂原子的脱氧尿苷三磷酸酶抑制剂 |
| KR20200036063A (ko) | 2014-01-21 | 2020-04-06 | 얀센 파마슈티카 엔.브이. | 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도 |
| KR20220038826A (ko) | 2014-01-21 | 2022-03-29 | 얀센 파마슈티카 엔.브이. | 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도 |
| WO2017006271A1 (en) | 2015-07-08 | 2017-01-12 | University Of Southern California | Deoxyuridine triphosphatase inhibitors containing amino sulfonyl linkage |
| WO2017006270A1 (en) | 2015-07-08 | 2017-01-12 | University Of Southern California | Deoxyuridine triphosphatase inhibitors |
| US10544105B2 (en) | 2015-07-08 | 2020-01-28 | Cv6 Therapeutics (Ni) Limited | Deoxyuridine triphosphatase inhibitors containing cyclopropano linkage |
| WO2017006282A1 (en) | 2015-07-08 | 2017-01-12 | Cv6 Therapeutics (Ni) Limited | Hydantoin containing deoxyuridine triphosphatase inhibitors |
| US10722484B2 (en) | 2016-03-09 | 2020-07-28 | K-Gen, Inc. | Methods of cancer treatment |
| WO2018098207A1 (en) | 2016-11-23 | 2018-05-31 | Cv6 Therapeutics (Ni) Limited | Hydantoin containing deoxyuridine triphosphatase inhibitors |
| WO2018098208A1 (en) | 2016-11-23 | 2018-05-31 | Cv6 Therapeutics (Ni) Limited | Nitrogen ring linked deoxyuridine triphosphatase inhibitors |
| WO2018098209A1 (en) | 2016-11-23 | 2018-05-31 | Cv6 Therapeutics (Ni) Limited | Amino sulfonyl compounds |
| US10858344B2 (en) | 2016-11-23 | 2020-12-08 | Cv6 Therapeutics (Ni) Limited | Hydantoin containing deoxyuridine triphosphatase inhibitors |
| US11174271B2 (en) | 2016-11-23 | 2021-11-16 | Cv6 Therapeutics (Ni) Limited | 6-membered uracil isosteres |
| WO2018128720A1 (en) | 2017-01-05 | 2018-07-12 | Cv6 Therapeutics (Ni) Limited | Uracil containing compounds |
| CN119954663B (zh) * | 2025-02-06 | 2026-02-13 | 山东师范大学 | 一种针对氨基/叠氮/羧基化合物的稳定同位素标记试剂及其制备方法与应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0662529B2 (ja) * | 1984-07-13 | 1994-08-17 | 三共株式会社 | アミノ酸誘導体 |
| AU598750B2 (en) * | 1985-09-27 | 1990-07-05 | Mitsubishi Chemical Corporation | Phenylalanine derivative and proteinase inhibitor |
| US5580979A (en) * | 1994-03-15 | 1996-12-03 | Trustees Of Tufts University | Phosphotyrosine peptidomimetics for inhibiting SH2 domain interactions |
| US5716929A (en) * | 1994-06-17 | 1998-02-10 | Vertex Pharmaceuticals, Inc. | Inhibitors of interleukin-1β converting enzyme |
| AU4972096A (en) * | 1995-02-01 | 1996-08-21 | Affymax Technologies N.V. | Peptides and compounds that bind to sh2 domains |
| AU4440496A (en) * | 1995-02-10 | 1996-08-22 | Smithkline Beecham Corporation | Use of src SH2 specific compounds to treat a bone resorption disease |
| WO1997012903A1 (en) * | 1995-10-04 | 1997-04-10 | Warner-Lambert Company | Compounds, compositions and methods for inhibiting the binding of proteins containing an sh2 domain to cognate phosphorylated proteins |
| AU2277597A (en) * | 1996-02-23 | 1997-09-10 | Ariad Pharmaceuticals, Inc. | New inhibitors of sh2-mediated processes |
-
1998
- 1998-12-09 AT AT98962022T patent/ATE388139T1/de active
- 1998-12-09 AU AU17194/99A patent/AU1719499A/en not_active Abandoned
- 1998-12-09 WO PCT/US1998/026123 patent/WO1999031066A1/en not_active Ceased
- 1998-12-09 JP JP2000538993A patent/JP4524039B2/ja not_active Expired - Lifetime
- 1998-12-09 EP EP98962022A patent/EP1045836B1/de not_active Expired - Lifetime
- 1998-12-09 CA CA002315113A patent/CA2315113C/en not_active Expired - Lifetime
- 1998-12-09 DE DE69839221T patent/DE69839221T2/de not_active Expired - Lifetime
- 1998-12-09 US US09/208,113 patent/US6054470A/en not_active Expired - Lifetime
- 1998-12-09 ES ES98962022T patent/ES2302363T3/es not_active Expired - Lifetime
- 1998-12-17 UY UY25313A patent/UY25313A1/es not_active Application Discontinuation
- 1998-12-17 CO CO98075225A patent/CO4990963A1/es unknown
- 1998-12-17 ZA ZA9811570A patent/ZA9811570B/xx unknown
- 1998-12-18 AR ARP980106470A patent/AR017895A1/es unknown
-
1999
- 1999-11-12 US US09/438,629 patent/US6268365B1/en not_active Expired - Lifetime
- 1999-11-12 US US09/438,647 patent/US6284768B1/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| AU1719499A (en) | 1999-07-05 |
| JP2003514762A (ja) | 2003-04-22 |
| ZA9811570B (en) | 1999-09-16 |
| CO4990963A1 (es) | 2000-12-26 |
| EP1045836B1 (de) | 2008-03-05 |
| DE69839221T2 (de) | 2009-04-30 |
| AR017895A1 (es) | 2001-10-24 |
| US6054470A (en) | 2000-04-25 |
| JP4524039B2 (ja) | 2010-08-11 |
| ES2302363T3 (es) | 2008-07-01 |
| US6284768B1 (en) | 2001-09-04 |
| UY25313A1 (es) | 2000-12-29 |
| WO1999031066A1 (en) | 1999-06-24 |
| EP1045836A1 (de) | 2000-10-25 |
| CA2315113C (en) | 2009-12-08 |
| DE69839221D1 (de) | 2008-04-17 |
| CA2315113A1 (en) | 1999-06-24 |
| US6268365B1 (en) | 2001-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE388139T1 (de) | Pyridone als hemmer der sh2-domäne der src- familie | |
| IS5574A (is) | Útskiptir Xa-þáttar oxóasaheterósýklýl-tálmar | |
| DE69820005D1 (de) | Detektion der Wellenformveränderung verursacht durch chromatische Dispersion | |
| ID24638A (id) | Senyawa-senyawa anti aritmia bispidina | |
| DE19881732D2 (de) | 2-Phenyl-substituierte Imidazotriazinone als Phoshodiesterase Inhibitoren | |
| DE60028307D1 (de) | Eliminierung von interferenzsignalen | |
| DE60043145D1 (de) | Schadendetektion von Motorteilen | |
| DE60020100D1 (de) | Dimerverbindungen und als inhibitoren der neuramidinase | |
| DE69930518D1 (de) | Als antikrebsmittel verwendbare alkinyl-substituierte chinolin-2-on-derivate | |
| DK1073639T3 (da) | Chinolinderivater | |
| ATE250036T1 (de) | Chinolinderivate | |
| DE69818248D1 (de) | Chinolin- und chinazolin-derivate als crf antagonisten | |
| DE69628334D1 (de) | Chinolin derivate als nk3 antagoniste | |
| NO20001192L (no) | PÕvisning av rørlekkasje | |
| ATE214381T1 (de) | Thiazole derivate als protein kinase c inhibitoren | |
| ATE229005T1 (de) | Chinolinderivate | |
| DE69233356D1 (de) | Carbostyrilderivate als Phosphodiesterase-Hemmstoffe | |
| DE69927879D1 (de) | Feststellung ungewöhnlicher Wellenformen | |
| ATE279397T1 (de) | Phtalazine derivate phosphodiesterase 4 inhibitoren | |
| ID24374A (id) | Komposisi-komposisi parenteral alatrofloksasin | |
| ATE240943T1 (de) | Isochinolin derivate als urokinase inhibitoren | |
| ID25740A (id) | Rekitan perapat rumahan sungkup sumur dengan aspek pendukung | |
| EP1169476A4 (de) | Erkennung von melanoma | |
| ATE260259T1 (de) | Substituierte isochinolinderivate und ihre verwendung als anticonvulsiva | |
| DE60123744D1 (de) | Detektion einer abnormalen Aufzeichnung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1045836 Country of ref document: EP |